The prostanoid 15-Deoxy-Δ 12,14-prostaglandin-J2 reduces lung inflammation and protects mice against lethal influenza infection

Journal of Infectious Diseases

Volumn 205, Issue 4, 2012, Pages 621-630

  Cloutier, Alexandre ^a   Marois, Isabelle ^a   Cloutier, Diane ^a   Verreault, Catherine ^a   Cantin, André M ^a   Richter, Martin V ^a  

^a UNIVERSITÉ DE SHERBROOKE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; 2 CHLORO 5 NITROBENZANILIDE; CHEMOKINE; CYTOKINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA ANTAGONIST; PROSTANOID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; GENE EXPRESSION; IMMUNE RESPONSE; IN VITRO STUDY; INFLUENZA; MORBIDITY; MORTALITY; MOUSE; NONHUMAN; PATHOGENICITY; PNEUMONIA; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; VIRUS LOAD;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CYTOKINES; FEMALE; LUNG; MICE; MICE, INBRED C57BL; ORTHOMYXOVIRIDAE INFECTIONS; PNEUMONIA; PPAR GAMMA; PROSTAGLANDIN D2; SURVIVAL ANALYSIS;

EID: 84856242482     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir804     Document Type: Article

References (48)

1. De Jong MD, Simmons CP, Thanh TT, et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med 2006; 12:1203-7. (Pubitemid 44527358)
2. To KK, Hung IF, Li IW, et al. Delayed clearance of viral load and marked cytokine activation in severe cases of pandemic H1N1 2009 influenza virus infection. Clin Infect Dis 2010; 50:850-9.
3. Mauad T, Hajjar LA, Callegari GD, et al. Lung pathology in fatal novel human influenza A (H1N1) infection. Am J Respir Crit Care Med 2010; 181:72-9.
4. Simmons C, Farrar J. Insights into inflammation and influenza. N Engl J Med 2008; 359:1621-3.
5. Kobasa D, Jones SM, Shinya K, et al. Aberrant innate immune response in lethal infection of macaques with the 1918 influenza virus. Nature 2007; 445:319-23. (Pubitemid 46122819)
6. Kash JC, Tumpey TM, Proll SC, et al. Genomic analysis of increased host immune and cell death responses induced by 1918 influenza virus. Nature 2006; 443:578-81. (Pubitemid 44527293)
7. Perrone LA, Plowden JK, Garcia-Sastre A, Katz JM, Tumpey TM. H5N1 and 1918 pandemic influenza virus infection results in early and excessive infiltration of macrophages and neutrophils in the lungs of mice. PLoS Pathog 2008; 4:e1000115.
8. Fedson DS. Confronting the next influenza pandemic with antiinflammatory and immunomodulatory agents: why they are needed and how they might work. Influenza Other Respi Viruses 2009; 3: 129-42.
9. Rainsford KD. Influenza ("bird flu"), inflammation and antiinflammatory/analgesic drugs. Inflammopharmacology 2006; 14:2-9.
10. Salomon R, Webster RG. The influenza virus enigma. Cell 2009; 136: 402-10.
11. Budd A, Alleva L, Alsharifi M, et al. Increased survival after gemfibrozil treatment of severe mouse influenza. Antimicrob Agents Chemother 2007; 51:2965-8. (Pubitemid 47206237)
12. Aldridge JR Jr, Moseley CE, Boltz DA, et al. TNF/iNOS-producing dendritic cells are the necessary evil of lethal influenza virus infection. Proc Natl Acad Sci USA 2009; 106:5306-11.
13. Carey MA, Bradbury JA, Rebolloso YD, Graves JP, Zeldin DC, Germolec DR. Pharmacologic inhibition of COX-1 and COX-2 in influenza A viral infection in mice. PLoS One 2010; 5:e11610.
14. Salomon R, Hoffmann E, Webster RG. Inhibition of the cytokine response does not protect against lethal H5N1 influenza infection. Proc Natl Acad Sci USA 2007; 104:12479-81. (Pubitemid 47206163)
15. Szretter KJ, Gangappa S, Lu X, et al. Role of host cytokine responses in the pathogenesis of avian H5N1 influenza viruses in mice. J Virol 2007; 81:2736-44. (Pubitemid 46447038)
16. Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 1998; 391:82-6. (Pubitemid 28079219)
17. Azuma Y, Shinohara M, Wang PL, Ohura K. 15-Deoxy-delta(12,14)- prostaglandin J(2) inhibits IL-10 and IL-12 production by macrophages. Biochem Biophys Res Commun 2001; 283:344-6. (Pubitemid 32924695)
18. Cloutier A, Ear T, Blais-Charron E, Dubois CM, McDonald PP. Differential involvement of NF-kappaB and MAP kinase pathways in the generation of inflammatory cytokines by human neutrophils. J Leukoc Biol 2007; 81:567-77. (Pubitemid 46198409)
19. Ruiz PA, Kim SC, Sartor RB, Haller D. 15-Deoxy-delta12,14-prostaglandin J2-mediated ERK signaling inhibits gram-negative bacteria-induced RelA phosphorylation and interleukin-6 gene expression in intestinal epithelial cells through modulation of protein phosphatase 2A activity. J Biol Chem 2004; 279:36103-11. (Pubitemid 39100618)
20. Appel S, Mirakaj V, Bringmann A,Weck MM, Grunebach F, Brossart P. PPAR-gamma agonists inhibit toll-like receptor-mediated activation of dendritic cells via the MAP kinase and NF-kappaB pathways. Blood 2005; 106:3888-94. (Pubitemid 41739028)
21. Mochizuki M, Ishii Y, Itoh K, et al. Role of 15-deoxy delta(12,14) prostaglandin J2 and Nrf2 pathways in protection against acute lung injury. Am J Respir Crit Care Med 2005; 171:1260-6. (Pubitemid 40740733)
22. Chatterjee PK, Patel NS, Cuzzocrea S, et al. The cyclopentenone prostaglandin 15-deoxy-delta(12,14)-prostaglandin J2 ameliorates ischemic acute renal failure. Cardiovasc Res 2004; 61:630-43. (Pubitemid 38210168)
23. Hashimoto K, Ethridge RT, Saito H, Rajaraman S, Evers BM. The PPARgamma ligand, 15d-PGJ2, attenuates the severity of ceruleininduced acute pancreatitis. Pancreas 2003; 27:58-66. (Pubitemid 36775980)
24. Zingarelli B, Sheehan M, Hake PW, O'Connor M, Denenberg A, Cook JA. Peroxisome proliferator activator receptor-gamma ligands, 15-deoxy-delta(12,14)- prostaglandin J2 and ciglitazone, reduce systemic inflammation in polymicrobial sepsis by modulation of signal transduction pathways. J Immunol 2003; 171:6827-37. (Pubitemid 37532118)
25. Kawahito Y, Kondo M, Tsubouchi Y, et al. 15-Deoxy-delta(12,14)-PGJ(2) induces synoviocyte apoptosis and suppresses adjuvantinduced arthritis in rats. J Clin Invest 2000; 106:189-97. (Pubitemid 30483122)
26. Cuzzocrea S, Ianaro A, Wayman NS, et al. The cyclopentenone prostaglandin 15-deoxy-delta(12,14)-PGJ2 attenuates the development of colon injury caused by dinitrobenzene sulphonic acid in the rat. Br J Pharmacol 2003; 138:678-88. (Pubitemid 36315316)
27. Straus DS, Pascual G, Li M, et al. 15-Deoxy-delta 12,14-prostaglandin J2 inhibits multiple steps in the NF-kappa B signaling pathway. Proc Natl Acad Sci USA 2000; 97:4844-9. (Pubitemid 30238645)
28. Rossi A, Kapahi P, Natoli G, et al. Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IkappaB kinase. Nature 2000; 403:103-8. (Pubitemid 30038530)
29. Castrillo A, Diaz-Guerra MJ, Hortelano S, Martin-Sanz P, Bosca L. Inhibition of IkappaB kinase and IkappaB phosphorylation by 15-deoxy-delta(12, 14)-prostaglandin J(2) in activated murine macrophages. Mol Cell Biol 2000; 20:1692-8. (Pubitemid 30100188)
30. Cernuda-Morollon E, Pineda-Molina E, Canada FJ, Perez-Sala D. 15-Deoxy-delta 12,14-prostaglandin J2 inhibition of NF-kappaB-DNA binding through covalent modification of the p50 subunit. J Biol Chem 2001; 276:35530-6.
31. Straus DS, Glass CK. Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms. Trends Immunol 2007; 28:551-8. (Pubitemid 350101420)
32. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001; 25:402-8. (Pubitemid 34164012)
33. Stambas J, Guillonneau C, Kedzierska K, Mintern JD, Doherty PC, La Gruta NL. Killer T cells in influenza. Pharmacol Ther 2008; 120: 186-96.
34. Tumpey TM, Garcia-Sastre A, Taubenberger JK, et al. Pathogenicity of influenza viruses with genes from the 1918 pandemic virus: functional roles of alveolar macrophages and neutrophils in limiting virus replication and mortality in mice. J Virol 2005; 79:14933-44. (Pubitemid 41636290)
35. Cheung CY, Poon LL, Lau AS, et al. Induction of proinflammatory cytokines in human macrophages by influenza A (H5N1) viruses: a mechanism for the unusual severity of human disease? Lancet 2002; 360:1831-7. (Pubitemid 35449422)
36. Hussell T, Pennycook A, Openshaw PJ. Inhibition of tumor necrosis factor reduces the severity of virus-specific lung immunopathology. Eur J Immunol 2001; 31:2566-73. (Pubitemid 32898723)
37. Perrone LA, Szretter KJ, Katz JM, Mizgerd JP, Tumpey TM. Mice lacking both TNF and IL-1 receptors exhibit reduced lung inflammation and delay in onset of death following infection with a highly virulent H5N1 virus. J Infect Dis 2010; 202:1161-70.
38. Dawson TC, BeckMA, Kuziel WA, Henderson F, Maeda N. Contrasting effects of CCR5 and CCR2 deficiency in the pulmonary inflammatory response to influenza A virus. Am J Pathol 2000; 156:1951-9. (Pubitemid 30641764)
39. Lin KL, Sweeney S, Kang BD, Ramsburg E, Gunn MD. CCR2-antagonist prophylaxis reduces pulmonary immune pathology and markedly improves survival during influenza infection. J Immunol 2011; 186: 508-15.
40. Zheng BJ, Chan KW, Lin YP, et al. Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virus. Proc Natl Acad Sci USA 2008; 105:8091-6.
41. Bauer CM, Zavitz CC, Botelho FM, et al. Treating viral exacerbations of chronic obstructive pulmonary disease: insights from a mouse model of cigarette smoke and H1N1 influenza infection. PLoS One 2010; 5:e13251.
42. Bassaganya-Riera J, Song R, Roberts PC, Hontecillas R. PPAR-gamma activation as an anti-inflammatory therapy for respiratory virus infections. Viral Immunol 2010; 23:343-52.
43. Moseley CE, Webster RG, Aldridge JR. Peroxisome proliferatoractivated receptor and AMP-activated protein kinase agonists protect against lethal influenza virus challenge in mice. Influenza Other Respi Viruses 2010; 4:307-11.
44. Ray DM, Akbiyik F, Phipps RP. The peroxisome proliferatoractivated receptor gamma (PPARgamma) ligands 15-deoxy-delta12, 14-prostaglandin J2 and ciglitazone induce human B lymphocyte and B cell lymphoma apoptosis by PPARgamma-independent mechanisms. J Immunol 2006; 177:5068-76. (Pubitemid 44527577)
45. Soller M, Drose S, Brandt U, Brune B, von Knethen A. Mechanism of thiazolidinedione-dependent cell death in Jurkat T cells. Mol Pharmacol 2007; 71:1535-44. (Pubitemid 47010906)
46. Adachi M, Matsukura S, Tokunaga H, Kokubu F. Expression of cytokines on human bronchial epithelial cells induced by influenza virus A. Int Arch Allergy Immunol 1997; 113:307-11. (Pubitemid 27160796)
47. Arnold R, Konig W. Peroxisome-proliferator-activated receptorgamma agonists inhibit the release of proinflammatory cytokines from RSV-infected epithelial cells. Virology 2006; 346:427-39. (Pubitemid 43357886)
48. Kumagai M, Imaizumi T, Suzuki K, et al. 15-Deoxy-delta(12,14)- prostaglandin J2 inhibits the IL-1beta-induced expression of granulocyte-macrophage colony-stimulating factor in BEAS-2B bronchial epithelial cells. Tohoku J Exp Med 2004; 202:69-76. (Pubitemid 38489066)